Home › Companies › Nektar Therapeutics › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Nektar Therapeutics’s Form 8-K, filed June 5, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2026: 4 items on Nektar Therapeutics’s Form 8-K, filed June 5, 2026: 3 approved · 1 passed (calculated).
Significant dissent: 1 director (27.4% against); 1 equity or compensation plan (27.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Two Seas Capital LP (13F, 9.8%, as of September 30, 2026)
Explore Nektar Therapeutics in the interactive database Compare manager voting policies
These tallies are Nektar Therapeutics’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Howard W. Robin | 13,164,879 | 4,975,288 | 286,175 | -- | 4,588,835 | 73% | Passed (calculated) | — |
| 2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares | 13,160,661 | 4,902,925 | 362,756 | -- | 4,588,835 | 73% | Approved | — |
| 3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 22,591,556 | 118,592 | 305,029 | -- | 0 | 99.5% | Approved | — |
| 4. Proposal to approve the non-binding advisory resolution regarding our executive compensation | 18,154,226 | 161,005 | 111,111 | -- | 4,588,835 | 99.1% | Approved | — |
This meeting is also recorded here as June 5, 2026; both records come from the same filing, so the date should be checked against it.
Source: Nektar Therapeutics, Form 8-K, filed with the SEC on June 5, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
179 asset managers disclosed a vote on at least one Nektar Therapeutics item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Howard W. Robin
Nektar Therapeutics’s own tally for this item (“Elect Director: Howard W. Robin”): 13,164,879 for, 4,975,288 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 3,036,968 for, 2,695,051 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 299,656 | 2,436,304 | 0 | 0 | Mixed |
| Vanguard | 1,252,287 | 2,368 | 1 | 0 | For |
| Invesco | 353,993 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 246,634 | 0 | 0 | 0 | For |
| Lord Abbett | 234,845 | 0 | 0 | 0 | For |
| Charles Schwab | 168,104 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 499 | 165,939 | 0 | 0 | Against |
| Principal | 0 | 90,281 | 0 | 0 | Against |
| DWS | 90,000 | 0 | 0 | 0 | For |
| BlackRock | 83,578 | 0 | 0 | 0 | For |
| State Street | 73,361 | 53 | 0 | 0 | For |
| Russell Investments | 60,150 | 0 | 0 | 0 | For |
| MassMutual | 42,037 | 0 | 0 | 0 | For |
| Equitable | 26,743 | 0 | 0 | 0 | For |
| ALGER FUNDS | 19,035 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 17,092 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 10,431 | 0 | 0 | 0 | For |
| Morgan Stanley | 10,394 | 0 | 0 | 0 | For |
| MML Series Investment Fund II | 10,221 | 0 | 0 | 0 | For |
| Empower | 8,646 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,760 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 4,748 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,000 | 0 | 0 | 0 | For |
| ProShares | 3,159 | 0 | 0 | 0 | For |
| Victory Capital | 3,127 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
73% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 3,000,000 SHARES.
Nektar Therapeutics’s own tally for this item (“2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares”): 13,160,661 for, 4,902,925 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares was approved with the following votes.”
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 41 asset managers below reported 3,321,502 for, 2,446,530 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 299,656 | 2,436,304 | 0 | 0 | Mixed |
| Vanguard | 1,252,287 | 2,367 | 1 | 0 | For |
| Invesco | 353,993 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 246,634 | 0 | 0 | 0 | For |
| Lord Abbett | 234,845 | 0 | 0 | 0 | For |
| Charles Schwab | 168,104 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 165,939 | 499 | 0 | 0 | For |
| Principal | 90,281 | 0 | 0 | 0 | For |
| DWS | 90,000 | 0 | 0 | 0 | For |
| BlackRock | 83,578 | 0 | 0 | 0 | For |
| State Street | 73,361 | 53 | 0 | 0 | For |
| Russell Investments | 60,150 | 0 | 0 | 0 | For |
| MassMutual | 42,037 | 0 | 0 | 0 | For |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 31,320 | 0 | 0 | 0 | For |
| Equitable | 26,743 | 0 | 0 | 0 | For |
| ALGER FUNDS | 19,035 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 17,092 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 10,431 | 0 | 0 | 0 | For |
| Morgan Stanley | 10,394 | 0 | 0 | 0 | For |
| MML Series Investment Fund II | 10,221 | 0 | 0 | 0 | For |
| Empower | 8,646 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,760 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 4,748 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 0 | 4,680 | 0 | 0 | Against |
| T. Rowe Price | 4,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
99.1% Approved · of votes cast
Prior year: 96.0% for (May 23, 2025 meeting) ▲ 3.2 pts
Description as filed by funds: To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).
Nektar Therapeutics’s own tally for this item (“4. Proposal to approve the non-binding advisory resolution regarding our executive compensation”): 18,154,226 for, 161,005 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Nektar Therapeutics’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (3 managers, 1,255 for, 3,057 abstained).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,735,960 | 0 | 0 | 0 | For |
| Vanguard | 1,254,655 | 0 | 0 | 0 | For |
| Invesco | 353,993 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 246,634 | 0 | 0 | 0 | For |
| Lord Abbett | 234,845 | 0 | 0 | 0 | For |
| Charles Schwab | 168,104 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 166,438 | 0 | 0 | 0 | For |
| Principal | 90,281 | 0 | 0 | 0 | For |
| DWS | 90,000 | 0 | 0 | 0 | For |
| BlackRock | 83,578 | 0 | 0 | 0 | For |
| State Street | 73,414 | 0 | 0 | 0 | For |
| Russell Investments | 60,150 | 0 | 0 | 0 | For |
| MassMutual | 42,037 | 0 | 0 | 0 | For |
| Equitable | 26,743 | 0 | 0 | 0 | For |
| ALGER FUNDS | 19,035 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 17,092 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 10,431 | 0 | 0 | 0 | For |
| Morgan Stanley | 10,394 | 0 | 0 | 0 | For |
| MML Series Investment Fund II | 10,221 | 0 | 0 | 0 | For |
| Empower | 8,646 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,760 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 4,748 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,000 | 0 | 0 | 0 | For |
| ProShares | 3,159 | 0 | 0 | 0 | For |
| Victory Capital | 3,127 | 0 | 0 | 0 | For |
Fund voting reports, all 37 managers: 5,731,843 for, 21 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,301,617 | 0 | 0 | 0 | For |
| BVF INC/IL | 2,559,595 | 0 | 0 | 0 | For |
| Two Seas Capital LP | 1,991,046 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 550,000 | 0 | 0 | 0 | For |
| BlackRock | 465,836 | 0 | 0 | 0 | For |
| Invesco | 454,326 | 0 | 0 | 0 | For |
| Woodline Partners LP | 407,278 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 351,849 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 330,449 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 279,150 | 0 | 0 | 0 | For |
| Two Sigma | 274,347 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 257,418 | 0 | 0 | 0 | For |
| Prosight Management, LP | 233,115 | 0 | 0 | 0 | For |
| State Street | 229,909 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 225,040 | 0 | 0 | 0 | For |
| Vanguard | 205,842 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 196,900 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 193,335 | 0 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 181,182 | 0 | 0 | 0 | For |
| Charles Schwab | 168,115 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 165,178 | 0 | 0 | 0 | For |
| Citadel | 164,694 | 0 | 0 | 0 | For |
| Tetragon Partners GP Ltd | 103,037 | 0 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 100,623 | 0 | 0 | 0 | For |
| Russell Investments | 99,102 | 0 | 0 | 0 | For |
Institutional-manager reports, all 152 managers: 15,502,011 for, 29,240 against, 3,068 abstained, 10,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.5% Approved · of votes cast
Prior year: 98.9% for (May 23, 2025 meeting) ▲ 0.6 pts
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Nektar Therapeutics’s own tally for this item (“3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 22,591,556 for, 118,592 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with the following votes.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 5,730,768 for, 1,250 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,735,960 | 0 | 0 | 0 | For |
| Vanguard | 1,253,524 | 1,130 | 1 | 0 | For |
| Invesco | 353,993 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 246,634 | 0 | 0 | 0 | For |
| Lord Abbett | 234,845 | 0 | 0 | 0 | For |
| Charles Schwab | 168,104 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 166,438 | 0 | 0 | 0 | For |
| Principal | 90,281 | 0 | 0 | 0 | For |
| DWS | 90,000 | 0 | 0 | 0 | For |
| BlackRock | 83,578 | 0 | 0 | 0 | For |
| State Street | 73,402 | 12 | 0 | 0 | For |
| Russell Investments | 60,150 | 0 | 0 | 0 | For |
| MassMutual | 42,037 | 0 | 0 | 0 | For |
| Equitable | 26,743 | 0 | 0 | 0 | For |
| ALGER FUNDS | 19,035 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 17,092 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 10,431 | 0 | 0 | 0 | For |
| Morgan Stanley | 10,394 | 0 | 0 | 0 | For |
| MML Series Investment Fund II | 10,221 | 0 | 0 | 0 | For |
| Empower | 8,646 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,760 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 4,748 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,000 | 0 | 0 | 0 | For |
| ProShares | 3,159 | 0 | 0 | 0 | For |
| Victory Capital | 3,127 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 33,786,032 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 8.10% |
| 2 | Vanguard | 3.71% |
| 3 | Invesco | 1.05% |
| 4 | PRIMECAP Odyssey Funds | 0.73% |
| 5 | Lord Abbett | 0.70% |
| 6 | Charles Schwab | 0.50% |
| 7 | RBB FUND, INC. | 0.49% |
| 8 | Principal | 0.27% |
| 9 | DWS | 0.27% |
| 10 | BlackRock | 0.25% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.73% |
| 2 | BVF INC/IL | 7.58% |
| 3 | Two Seas Capital LP | 5.89% |
| 4 | GREAT POINT PARTNERS LLC | 1.63% |
| 5 | BlackRock | 1.38% |
| 6 | Invesco | 1.34% |
| 7 | Woodline Partners LP | 1.21% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.04% |
| 9 | LORD, ABBETT & CO. LLC | 0.98% |
| 10 | PRIMECAP MANAGEMENT CO/CA/ | 0.83% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 4,303,188 | 12.74% | Form 13F, quarter ended March 31, 2026 |
| FMR LLC | 3,036,761 | 8.99% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| BVF PARTNERS L P/IL | 2,391,075 | 7.08% | Schedule 13G, filed August 14, 2026 |
| Entities affiliated with Two Seas Global (Master) Fund LP | 1,959,178 | 5.80% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| Entities affiliated with BVF Inc. | 1,276,595 | 3.78% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| Vanguard Group | 1,027,089 | 3.04% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 930,741 | 2.75% | Form 13F, quarter ended March 31, 2026 |
| G1 Execution Services, LLC | 809,967 | 2.40% | Schedule 13G, filed February 13, 2026 |
| BlackRock | 692,650 | 2.05% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 665,431 | 1.97% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 33,786,032 shares outstanding, as reported by Nektar Therapeutics on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Nektar Therapeutics's shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 179 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 577 separate fund positions. On the most widely held item on that ballot — To approve a non-binding advisory resolution regarding our executive compensation (a… — Nektar Therapeutics's filing reports the proposal as approved, with 99.1% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Nektar Therapeutics's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Nektar Therapeutics’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Nektar Therapeutics proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Nektar Therapeutics (NKTR) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/nektar-therapeutics/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.